vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and Maase Inc. (MAAS). Click either name above to swap in a different company.
Coherus Oncology, Inc. is the larger business by last-quarter revenue ($12.7M vs $9.9M, roughly 1.3× Maase Inc.).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
CHRS vs MAAS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $9.9M |
| Net Profit | $-37.6M | — |
| Gross Margin | 68.3% | 78.7% |
| Operating Margin | -359.9% | -55.9% |
| Net Margin | -295.3% | — |
| Revenue YoY | 64.9% | — |
| Net Profit YoY | 25.7% | — |
| EPS (diluted) | $-0.34 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | — | ||
| Q3 25 | $11.6M | — | ||
| Q2 25 | $10.3M | — | ||
| Q2 24 | $10.3M | — | ||
| Q3 23 | $74.6M | — | ||
| Q2 23 | $58.7M | — | ||
| Q1 23 | $32.4M | — | ||
| Q4 22 | $45.4M | $9.9M |
| Q4 25 | $-37.6M | — | ||
| Q3 25 | $-35.5M | — | ||
| Q2 25 | $297.8M | — | ||
| Q2 24 | $-12.9M | — | ||
| Q3 23 | $-39.6M | — | ||
| Q2 23 | $-42.9M | — | ||
| Q1 23 | $-75.7M | — | ||
| Q4 22 | $-58.9M | — |
| Q4 25 | 68.3% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 66.9% | — | ||
| Q2 24 | 82.4% | — | ||
| Q3 23 | 56.1% | — | ||
| Q2 23 | 57.7% | — | ||
| Q1 23 | 48.0% | — | ||
| Q4 22 | 68.7% | 78.7% |
| Q4 25 | -359.9% | — | ||
| Q3 25 | -383.1% | — | ||
| Q2 25 | -443.6% | — | ||
| Q2 24 | -384.9% | — | ||
| Q3 23 | -42.9% | — | ||
| Q2 23 | -58.8% | — | ||
| Q1 23 | -208.9% | — | ||
| Q4 22 | -113.5% | -55.9% |
| Q4 25 | -295.3% | — | ||
| Q3 25 | -307.1% | — | ||
| Q2 25 | 2903.9% | — | ||
| Q2 24 | -125.5% | — | ||
| Q3 23 | -53.2% | — | ||
| Q2 23 | -73.0% | — | ||
| Q1 23 | -233.5% | — | ||
| Q4 22 | -129.8% | — |
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $2.57 | — | ||
| Q2 24 | $-0.11 | — | ||
| Q3 23 | $-0.41 | — | ||
| Q2 23 | $-0.49 | — | ||
| Q1 23 | $-0.96 | — | ||
| Q4 22 | $-0.76 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $10.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $61.0M | $31.6M |
| Total Assets | $258.3M | $47.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | — | ||
| Q3 25 | $191.7M | — | ||
| Q2 25 | $237.6M | — | ||
| Q2 24 | $159.2M | — | ||
| Q3 23 | $131.1M | — | ||
| Q2 23 | $144.7M | — | ||
| Q1 23 | $128.1M | — | ||
| Q4 22 | $128.1M | $10.9M |
| Q4 25 | $61.0M | — | ||
| Q3 25 | $87.8M | — | ||
| Q2 25 | $119.8M | — | ||
| Q2 24 | $-84.1M | — | ||
| Q3 23 | $-133.6M | — | ||
| Q2 23 | $-174.8M | — | ||
| Q1 23 | $-196.5M | — | ||
| Q4 22 | — | $31.6M |
| Q4 25 | $258.3M | — | ||
| Q3 25 | $516.5M | — | ||
| Q2 25 | $439.5M | — | ||
| Q2 24 | $674.9M | — | ||
| Q3 23 | $583.8M | — | ||
| Q2 23 | $469.6M | — | ||
| Q1 23 | $402.4M | — | ||
| Q4 22 | $480.8M | $47.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | $-18.2M |
| Free Cash FlowOCF − Capex | — | $-18.3M |
| FCF MarginFCF / Revenue | — | -184.4% |
| Capex IntensityCapex / Revenue | — | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | — | ||
| Q3 25 | $-46.3M | — | ||
| Q2 25 | $-46.6M | — | ||
| Q2 24 | $59.7M | — | ||
| Q3 23 | $-54.3M | — | ||
| Q2 23 | $-38.9M | — | ||
| Q1 23 | $-68.7M | — | ||
| Q4 22 | $-100.0M | $-18.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-39.0M | — | ||
| Q1 23 | $-68.9M | — | ||
| Q4 22 | $-100.0M | $-18.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -66.4% | — | ||
| Q1 23 | -212.4% | — | ||
| Q4 22 | -220.6% | -184.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | 0.2% | — | ||
| Q1 23 | 0.5% | — | ||
| Q4 22 | 0.2% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
